US Patent

US11365182 — Crystal modifications of odevixibat

Method of Use · Assigned to Albireo AB · Expires 2039-06-20 · 13y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects crystal modifications of the drug odevixibat, specifically modifications 1 and 2, and a process for preparing one of these modifications.

USPTO Abstract

The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3648 — Bylvay
U-3648 — Bylvay
U-3648 — Bylvay
U-3648 — Bylvay

Patent Metadata

Patent number
US11365182
Jurisdiction
US
Classification
Method of Use
Expires
2039-06-20
Drug substance claim
No
Drug product claim
No
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.